CRSP Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $313,950.00
Insider Selling (Last 12 Months): $5,714,378.34

CRISPR Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$314kbought$1.61MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

CRISPR Therapeutics Share Price & Price History

Current Price: $36.99
Price Change: Price Decrease of -1.05 (-2.76%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for CRSP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$36.99Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for CRISPR Therapeutics (NASDAQ:CRSP)

69.20% of CRISPR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CRSP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$251Mbought$50MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More on CRISPR Therapeutics

Today's Range

Now: $36.99
Low: $36.93
High: $38.20

50 Day Range

MA: $43.10
Low: $36.99
High: $53.02

52 Week Range

Now: $36.99
Low: $36.52
High: $68.39

Volume

1,595,765 shs

Average Volume

1,551,646 shs

Market Capitalization

$3.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Who are the company insiders with the largest holdings of CRISPR Therapeutics?

CRISPR Therapeutics' top insider shareholders include:
  1. Samarth Kulkarni (CEO)
  2. James R Kasinger (General Counsel)
  3. Julianne Bruno (COO)
  4. John Greene (Director)
  5. Raju Prasad (CFO)
Learn More about top insider investors at CRISPR Therapeutics.

Who are the major institutional investors of CRISPR Therapeutics?

CRISPR Therapeutics' top institutional shareholders include:
  1. ARK Investment Management LLC — 10.51%
  2. Capital International Investors — 10.24%
  3. T. Rowe Price Investment Management Inc. — 4.47%
  4. Sumitomo Mitsui Trust Group Inc. — 3.22%
  5. Nikko Asset Management Americas Inc. — 3.22%
  6. Vanguard Group Inc. — 2.03%
Learn More about top institutional investors of CRISPR Therapeutics stock.

Which institutional investors are selling CRISPR Therapeutics stock?

During the previous quarter, CRSP stock was sold by these institutional investors:
  1. Sumitomo Mitsui Trust Group Inc.
  2. Nikko Asset Management Americas Inc.
  3. Eagle Health Investments LP
  4. Millennium Management LLC
  5. Voloridge Investment Management LLC
  6. GTS Securities LLC
  7. Rafferty Asset Management LLC
  8. Loomis Sayles & Co. L P
In the last year, company insiders that have sold CRISPR Therapeutics company stock include:
  1. Samarth Kulkarni (CEO)
  2. James R Kasinger (General Counsel)
  3. Julianne Bruno (COO)
Learn More investors selling CRISPR Therapeutics stock.

Which institutional investors are buying CRISPR Therapeutics stock?

During the previous quarter, CRSP stock was acquired by institutional investors including:
  1. ARK Investment Management LLC
  2. T. Rowe Price Investment Management Inc.
  3. Capital International Investors
  4. Baker BROS. Advisors LP
  5. Norges Bank
  6. Contrarius Group Holdings Ltd
  7. IMC Chicago LLC
  8. Bank of America Corp DE